FOXO4-DRI for Sale: One Vial Size, Two Different Fills
Summary: Listings for this compound all describe the same object, so the useful skill is not comparing storefronts but reading which of a listing's claims a laboratory document could actually confirm.
This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.
Every listing offering FOXO4-DRI for sale describes the same object: a small glass vial holding 10 mg of white lyophilised powder, sold for laboratory use, with a purity figure above 98%. The listings vary far less than the material behind them does, which is why reading the claim structure matters more than comparing shopfronts.
Where readers actually buy it
Ascension Peptides — FOXO4-DRI
Research-grade FOXO4-DRI, tested by two outside labs and shipped from the US. The code below takes half off the vial.
The two published certificates cover different batches and disagree on net content: Kovera Labs assayed batch 55-05260628 at 11.41 mg and MZ Biolabs assayed lot 55-01260229 at 8.30 mg, both against a 10 mg label, which moves the real figure between $5.87 and $8.07/mg. Endotoxin and sterility screens appear on the Kovera batch only. The vendor spells the product FOX04 with a zero, including in the link. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Batch certificates from two independent labs
- Free shipping over $250
- Ships same day if ordered before 2pm CST
Sold for laboratory research only and not for human consumption. FOXO4-DRI is not an approved medicine in any market and has never been tested in a human trial. These are affiliate links: we may earn a commission at no cost to you, and it does not change what we recommend. Prices checked September 2, 2026.
What is actually on the market
The market has settled on one format. A 10 mg vial of lyophilised powder under a crimped seal, with a certificate of analysis and a research-use designation. There is no 5 mg or 30 mg tier, so the usual per-milligram optimisation between vial sizes does not exist here.
Below that standard, things get less trustworthy. Occasional listings advertise blends pairing FOXO4-DRI with other compounds, which makes any single ingredient's contribution impossible to isolate and the certificate much harder to interpret. Others offer pre-reconstituted solution or a pre-loaded device. Treat those as a warning. Peptides are freeze-dried for shipping precisely because degradation accelerates in solution, and a supplier shipping it wet has either not considered stability or is relying on you not to.
You will also encounter the phrase "pharma grade". It has no regulatory meaning attached to a compound with no pharmaceutical approval in any market [3]. Here it is decoration.
Reading a listing claim by claim
The productive exercise is to take each claim a product page makes and ask what document could possibly support it.
| Listing claim | What would support it | How often that exists |
|---|---|---|
| "99%+ purity" | An HPLC chromatogram tied to your lot | Sometimes, and it is checkable |
| "Third-party tested" | A named laboratory with an address | Often absent, unfalsifiable without the name |
| "10 mg per vial" | A measured net content figure | Rarely published, and it is what varies |
| "Verified identity" | Mass spectrometry confirming the molecule | Occasionally, worth more than purity |
| "Endotoxin free" | An LAL screen on your specific batch | Batch-dependent, frequently generalised |
| "Pharma grade" | Nothing. No approved product exists | Never |
| "Research use only" | The vendor simply stating it | Always, and its absence is a warning |
The pattern is that purity is the claim most often made, while net content is the claim most often assumed and least often measured. Purity tells you what fraction of the material present is the intended molecule. It says nothing about how much material is present.
The number most listings never show
Ascension is unusual in publishing measured net content, and the numbers are the reason this article takes the shape it does.
Kovera Labs certified batch 55-05260628 in June 2026: 99.411% purity, net content 11.41 mg. MZ Biolabs analysed lot 55-01260229 in January 2026: 99.97% purity, net content 8.30 mg. Both vials carried a 10 mg label.
That is a spread of roughly 37% in delivered peptide across two batches of the same product, sitting behind two excellent purity figures. Both certificates are honest. They measure different things, and only one of those things is what buyers think they are reading.
The consequence is practical. Any concentration calculated from the label inherits the error. Dissolve a vial you believe holds 10 mg in 2 mL and you would record 5 mg/mL. If it actually held 8.30 mg, the true figure is 4.15 mg/mL, and everything drawn from it is roughly 17% short of intention. The peptide calculator does the arithmetic correctly, but only from the number you give it.
There is a quieter point in the same documents. The June batch was screened for endotoxins and microbial growth and passed both. The January batch was not screened for either. Testing scope belongs to a batch, so "endotoxin tested" describes one lot rather than the product.
What you are buying, chemically
Worth stating plainly, because listings rarely explain it and the name is opaque.
FOXO4-DRI is a synthetic peptide. DRI stands for D-retro-inverso: it is assembled from D-amino acids, the mirror image of the form biology uses, in reversed sequence. That construction presents a similar shape to the target while making the molecule much harder for proteases to degrade, which is why it survives long enough to do anything.
Its purpose is to disrupt the binding between the FOXO4 protein and p53 in senescent cells. That interaction is what keeps those cells alive despite their damage, so breaking it allows them to die while healthy cells are largely unaffected [1]. Reference data you can check independently: PubChem CID 167312269, CAS 2460055-10-9, molecular formula C228H388N86O64 [2].
The listing may spell it FOX04 with a digit zero. The compound is FOXO4, from Forkhead box protein O4, so the fourth character is a letter. It is a typo that spread into product URLs, not a sign of a counterfeit.
What the sale does not include
No prescriber, no label, no approved indication, no established dose, no safety profile, and no adverse-event reporting route. FOXO4-DRI has never been given to a human being in a registered trial, so the evidence that normally underpins all of those does not exist.
Returns in this market are generally limited to unopened, undamaged goods, which is narrower than it sounds once a vial has been handled. Domestic dispatch at least keeps customs out of the transaction and makes a US return address real.
- What sizes of FOXO4-DRI are sold?
- Effectively one, a 10 mg lyophilised vial. Unlike compounds offered at several strengths, there is no larger vial with a better per-milligram rate, so a listing offering unusual sizes deserves extra scrutiny rather than assumption of a better deal.
- Does a 99% purity claim mean the vial holds 10 mg?
- No, and conflating them is the most common error with these listings. Purity is the proportion of material that is the intended molecule; net content is how much material is present. The two published batches measured 11.41 mg and 8.30 mg while both testing above 99% pure.
- Why is pre-mixed FOXO4-DRI a red flag?
- Peptides degrade faster in solution than as dry powder, which is why the market ships them lyophilised. A supplier offering pre-dissolved material is either indifferent to stability or selling something whose potency on arrival cannot be assumed.
- What does "pharma grade" mean for this compound?
- Nothing. There is no approved pharmaceutical version of FOXO4-DRI in any market, so there is no pharmaceutical grade to meet. The phrase is marketing.